BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Apr 3, 2025 • 13min
On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress
CEO Jason Gardner describes Ampersand's platform that is designed to make medicines act at the site of disease. He also shares updates on partnerships with Pfizer and Pioneering Medicines, and highlights work in obesity, immuno-inflammation and immuno-oncology.
Apr 2, 2025 • 11min
BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round
CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to selectively degrade aggregates that cause neurodegeneration.
Apr 2, 2025 • 10min
Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office
Brian Goodman, Managing Director at Vida Ventures, shares insights from his extensive background in life sciences investing at MPM Bio Impact Fund. He discusses current trends in early-stage biotech investments, particularly in immunology, oncology, and neurology. The resilience of the sector amidst economic uncertainties is highlighted, along with the challenges and opportunities for innovation. Goodman also elaborates on Vida's strategies for supporting portfolio companies while seeking new investments, particularly within Boston's dynamic biotech landscape.
Apr 2, 2025 • 14min
After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection
He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes a precision medicine approach is overdue.
Apr 1, 2025 • 12min
BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed
He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has plans to use it for conditions like the surfactant protein deficiencies SP-B & ABCA3, alpha-1 antitrypsin deficiency, and IPF.
Mar 27, 2025 • 14min
Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry
Founder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better understand how diseases can have different profiles across diverse populations. Plus, how AI will play a role in this work.
Mar 27, 2025 • 11min
State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies
Mari Anne Snow describes the advantages she sees nanoparticles having over current modalities like viral vectors, LNPs, and others.
Mar 26, 2025 • 4min
State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies
He describes the 14th fund that Atlas raised at the end of last year, which was $450 million. Plus, his take on the environment, regulatory changes, China's impact on the sector, and improving biopharma's image.
Mar 26, 2025 • 8min
State of Possible: On the one-year anniversary of the spin-out of Seaport Therapeutics, Daphne Zohar describes the Glyph platform that powers it, and her thoughts on running depression trials
She describes the idea of leveraging Glyph to achieve oral dosing of medicines in cases where it would not be possible or tolerable. Plus, the lead clinical program, allopregnanolone, how the company thinks about avoiding high placebo responses in trials, and other programs.
Mar 26, 2025 • 13min
State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech
He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of concept of a gene editor. Plus, what's next for that program and sickle cell, and the decision to do an "over the wall" financing.
